Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 74, Issue 1, Pages 81-U127Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2015.08.031
Keywords
efficacy; follow-up; imiquimod; lentigo maligna; prognostic marker; recurrence topical; immunomodulators
Categories
Ask authors/readers for more resources
Background: More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM). Objective: We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod. Methods: This was a single-arm, open-label, nonrandomized, prospective study. Results: Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included: the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes. Limitations: Our study was a single-center, nonrandomized study. Conclusion: An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available